Navigation Links
Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.

NANJING, China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical Group (NYSE: SCR; ''Simcere''), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced that it has signed a definitive agreement to acquire a 70% equity interest in Wuhu Zhong Ren Pharmaceutical Co. Ltd. for a total cash consideration of RMB64.82 million (US $9.26 million). This transaction is consistent with Simcere's strategy to focus on first-to-market and innovative new drugs and expand its anti-cancer product portfolio.

Zhong Ren Pharmaceutical is a Chinese drug manufacturer specializing in the production of sustained release anti-tumor implants. Its key product SinoFuan (fluorouracil implant), is proven to effectively inhibit the growth of tumors, and is the only sustained release anti-tumor implant approved by the State Food and Drug Administration (SFDA). SinoFuan is commonly used to treat cancers of the digestive tract and is a favored choice for use during surgery. No similar product exists on the Chinese market today. Distribution of SinoFuan through Simcere's established marketing channels will enhance Simcere's offerings in the anti-cancer drug market, benefit cancer patients across China and create greater value for Simcere shareholders.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR; Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit .

For more information, please contact:

In China:

Frank Zhigang Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556-6666 x8818


Kejia Wu

Brunswick Group

Tel: +86-10-6566-4651


In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852-3512-5033


In the United States:

Michael Guerin

Brunswick Group

Tel: +1-212-333-3810


SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
2. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
3. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
4. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
5. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
6. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
7. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
8. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
9. Amylin Pharmaceuticals Reports First Quarter Financial Results
10. Complementary Excerpt Available from Best Practices: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications
11. Best Practice Database: Valuable Strategies for Pharmaceutical Product Launches
Post Your Comments:
(Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid ... America. As people age, more care is needed, especially with Alzheimer’s, dementia and ... professionals are being overworked. The forgotten part of this equation: 80 percent of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special ... 10% off of their purchase of lice treatment product. In addition, customers will receive ... a company spokesperson. “Finding lice is a sure way to ruin the holidays, so ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges faced ... and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities ... by parents and bring advice from parenting experts within their reach. As a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
Breaking Medicine Technology: